The combination of different HER2-targeted agents with complementary mechanisms has proven to be a robust approach to enhance the efficacy of therapies for HER2 + breast cancer (Figueroa-Magalhães et al., 2014; Elster et al., 2015). The gene discussed is ERBB2; the disease is breast carcinoma.